drugset

drugset / Trial / NCT00179660

Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)

NCT00179660 ↗

Phase 2 Completed 50 enrolled Celgene Corporation Prologue Research International · collab

NaSingle-groupOpen-labelTreatment

Summary

To determine the activity of lenalidomide in relapsed or refractory aggressive NHL.

Timeline

Start: 2005-08
Primary completion: 2008-06
Completion: 2008-06

Publications

Results Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008 Oct 20;26(30):4952-7. doi: 10.1200/JCO.2007.15.3429. Epub 2008 Jul 7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lenalidomide	Other / unclassified	25 mg	Oral

Indications